Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling

Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling

Abstract Background According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are urgently needed to improve outcomes for patients with advanced disease. T...

Full description

Bibliographic Details
Main Authors: Ruey-Shyang Soong, Ravi K. Anchoori, Richard B. S. Roden, Rou-Ling Cho, Yi-Chan Chen, Sheng-Chieh Tseng, Yun-Li Huang, Po-Cheng Liao, Yu-Chiau Shyu
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Cancer
Subjects:
Apoptosis
Hepatocellular carcinoma
NF-κB
Proteasome inhibitor
RA190
Online Access:http://link.springer.com/article/10.1186/s12885-020-06896-0

Internet

http://link.springer.com/article/10.1186/s12885-020-06896-0

Similar Items